NCCN pediatric acute lymphoblastic leukemia practice guidelines

ONCOLOGY

Volumn 10, Issue 12, 1996, Pages 1787-1794

  Pui, ^b  

^a NCCN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DAUNORUBICIN; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; HUMAN; PRACTICE GUIDELINE; REVIEW;

CHILD; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; RECURRENCE; RISK ASSESSMENT; SALVAGE THERAPY; SOCIAL SUPPORT;

EID: 0030473498     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Bennett JM, Catovsky D, Daniel MT, et al, The French-American-British (FAB) Co-operative Group: The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations. Br J Haematol 47:553-561, 1981.
2. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103:626-629, 1985.
3. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78:325-329, 1991.
4. Pui C-H, Behm FG, Crist WM: Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 82:343-362, 1993.
5. Pui C-H, Campana D, Crist WM: Toward a clinically useful classification of the acute leukemias. Leukemia 9:2154-2157, 1995.
6. Pui C-H, Crist WM, Look AT: Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 76:1449-1463, 1990.
7. Trueworthy R, Shuster J, Look T, et al: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: A Pediatric Oncology Group Study. J Clin Oncol 10:606-613, 1992.
8. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 85:2321-2330, 1995.
9. Rubnitz JE, Pui C-H, Shurtleff SA, et al: TEL gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance. J Clin Oncol 1996 (in press).
10. Pui C-H, Crist WM: Biology and treatment of acute lymphoblastic leukemia. J Pediatr 124:491-503, 1994.
11. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14(1):18-24, 1996.
12. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/ Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 12.740-747, 1994.
13. Steinherz PG, Redner A, Steinherz L, et al: Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering New York-II Protocol. Cancer 72:3120-3130, 1993.
14. Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61-66, 1991.
15. Gaynon PS, Steinherz PG, Bleyer WA, et al Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: A follow-up report of the Children's Cancer Group Study CCG-106. J Clin Oncol 11:2234-2242, 1993.
16. Tubergen DG, Gilchrist GS, O'Brien RT, et al: Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Childrens Cancer Group Report. J Clin Oncol 11:520-526, 1993.
17. Tubergen DG, Gilchrist GS, O'Brien RT, et al Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group Phase III Trial. J Clin Oncol 11:527-537, 1993.
18. Camitta B, Mahoney D, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 12:1383-1389, 1994.
19. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994.
20. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients, results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994.
21. Chessels JM, Bailey C, Richards SM for the Medical Research Council Working Party on Childhood Leukaemia: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 345:143-148, 1995.
22. Valsecchi MG, Rizzari C, Testi AM, et al for the Associazione Italiana di Ematologia ed Oncologia Pediatrica: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995.
23. Roberts WM, Rivera GK, Raimondi S, et al: Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Lancet 343.331-332, 1994.
24. Chessels JM, Bailey C, Wheeler K, et al: Bone marrow transplantation for high-risk childhood lymphoblastic leukaemia in first remission: Experience in MRC UKALL X. Lancet 340:565-569, 1992.
25. Bordigoni P, Vernant JP, Souillet G, et al: Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: A cooperative study of the Group d'Etude de la Greffe de Moelle Osseuse. J Clin Oncol 7:747-753, 1989.
26. DeWitte T, Awwad B, Boezeman J, et al: Role of allogeneic bone marrow transplantation in adolescent or adult patients with acute lymphoblastic leukaemia or lymphoblastic lymphoma in first remission. Bone Marrow Transplant 14:767-774, 1994.
27. Pui C-H, Frankel LS, Carroll AJ, et al: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21,q23): A collaborative study of 40 cases. Blood 77:440-447, 1991.
28. Behm FG, Raimondi SC, Frestedt JL, et al: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 87:2870-2877, 1996.
29. Campana D, Pui C-H: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416-1434, 1995.
30. Pui C-H, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 321:136-142, 1989.
31. Henze G, Fengler R, Hartmann R, et al: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85): A relapse study of the BFM Group. Blood 78:1166-1172, 1991.
32. Pui C-H, Bowman WP, Ochs J, et al: Cyclic combination chemotherapy for acute lymphoblastic leukemia recurring after elective cessation of therapy. Med Pedicar Oncol 12:21-26, 1988.
33. Winick NJ, Smith SD, Shuster J, et al: Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:271-278, 1993.
34. Ribeiro RC, Rivera GK, Hudson M, et al: An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 13:333-338, 1995.
35. Wofford MM, Smith SD, Shuster JJ, et al: Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 10:624-630, 1992.
36. Buchanan GR, Boyett JM, Pollock BH, et al: Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. Cancer 68:48-55, 1991.